rxstat › Classes › Antimetabolites

Antimetabolites: shortage status in Canada

4 of the 12 antimetabolites rxstat tracks are currently in shortage in Canada, including 1 designated Tier 3 (most serious) by Health Canada. When one drug in a class is short, demand often shifts to its alternatives, so related drugs can tighten too; each page below shows which manufacturers are affected and the latest recovery estimates.

Raltitrexed (Tomudex) Widespread shortage 1 of 1 reported products affected · est. return Dec 31, 2028 Capecitabine (Xeloda) Partial shortage 1 of 14 reported products affected Methotrexate (Nordimet) Partial shortage 3 of 31 reported products affected Pemetrexed (Alimta) Partial shortage 4 of 12 reported products affected Cytarabine Shortage anticipated 0 of 3 reported products affected Gemcitabine Shortage anticipated 0 of 9 reported products affected Azacitidine No current shortage Cladribine No current shortage Clofarabine (Clolar) No current shortage Fludarabine No current shortage Fluorouracil (Efudex) No current shortage Mercaptopurine (Purinethol) No current shortage

Guides: what to do when your medication is in shortage · how to read these statuses

Class groupings follow the WHO ATC classification in Health Canada's reports. Data reflects manufacturer mandatory filings; see methodology.